Society Guidelines

 

For Treatment of Atrial Fibrillation (Afib or AF)

Society Recommendation
STS (2017)1
“Surgical ablation for AF can be performed without additional risk of operative mortality or major morbidity, and is RECOMMENDED at the time of concomitant mitral operations to restore sinus rhythm. (Class I, Level A)” 
 
“Surgical ablation for AF can be performed without additional operative risk of mortality or major morbidity, and is RECOMMENDED at the time of concomitant isolated aortic valve replacement, isolated coronary artery bypass graft surgery, and aortic valve replacement plus coronary artery bypass graft operations to restore sinus rhythm. (Class I, Level B nonrandomized)” 
 
“In the treatment of AF, multidisciplinary heart team assessment, treatment planning, and long-term follow-up can be USEFUL AND BENEFICIAL to optimize patient outcomes. (Class I, Level C expert opinion)” 
 
“Surgical ablation for symptomatic AF in the absence of structural heart disease that is refractory to class I/III antiarrhythmic drugs or catheter-based therapy or both is REASONABLE as a primary stand-alone procedure, to restore sinus rhythm. (Class IIA, Level B randomized)” 
 
“Surgical ablation for symptomatic persistent or longstanding persistent AF in the absence of structural heart disease is REASONABLE, as a stand-alone procedure using the Cox-Maze III/IV lesion set compared with pulmonary vein isolation alone. (Class IIA, Level B nonrandomized)” 
HRS/EHRA/ECAS/ APHRS/SOLAECE (2017)2
“Surgical ablation of AF is recommended for paroxysmal, persistent, and long-standing persistent patients who are symptomatic AF refractory or intolerant to at least one Class 1 or 3 antiarrhythmic medication during concomitant open procedures (such as MVR). (Class I, Level B nonrandomized)”
 
“Surgical ablation of AF is recommended for paroxysmal, persistent, and long-standing persistent patients who are symptomatic AF prior to initiation of antiarrhythmic therapy with a class 1 or 3 antiarrhythmic medication during concomitant open procedures (such as MVR). (Class I, Level B nonrandomized)”
 
“Surgical ablation of AF is recommended for paroxysmal, persistent, and long-standing persistent patients who are symptomatic AF refractory or intolerant to at least one Class 1 or 3 antiarrhythmic medication during concomitant closed procedures (such as CABG and AVR). (Class I, Level B nonrandomized)”
 
“Surgical ablation of AF is reasonable for paroxysmal, persistent, and long-standing persistent patients who are symptomatic AF prior to initiation of antiarrhythmic therapy with a class 1 or 3 antiarrhythmic medication during concomitant closed procedures (such as CABG and AVR). (Class IIA, Level B nonrandomized)”
 
“Stand-Alone and Hybrid surgical ablation of AF is reasonable for persistent, and long-standing persistent patients who are symptomatic AF refractory or intolerant to at least one Class 1 or 3 antiarrhythmic medication and have failed one or more attempts at catheter ablation or prefer a surgical approach. (Class IIA, Level B nonrandomized)”
 
“Stand-Alone and Hybrid surgical ablation of AF can be considered for paroxysmal patients who are symptomatic AF refractory or intolerant to at least one Class 1 or 3 antiarrhythmic medication and have failed one or more attempts at catheter ablation or prefer a surgical approach. (Class IIB, Level B nonrandomized)”
ISMICS (2009)3
“Concomitant surgical ablation is recommended …. to increase the incidence of sinus rhythm both at short- and long-term follow-up …. to improve ejection fraction and exercise tolerance …. to reduce the risk of stroke and thromboembolic events …. and to improve long-term survival.”
UK NICE (2014)4
"Surgical ablation of AF should be considered in patients with persistent AF, or with symptomatic AF undergoing cardiothoracic surgery."
ESC (2010)5
"Surgical ablation of AF should be considered in patients with symptomatic or asymptomatic AF undergoing cardiac surgery."
 
"Minimally invasive surgical ablation of AF without concomitant cardiac surgery is feasible and may be performed in patients with symptomatic AF after failure of catheter ablation."

 

For Left Atrial Appendage Management (LAAM)

Society Recommendation
STS (2017)1
“It is REASONABLE to perform left atrial appendage excision or exclusion in conjunction with surgical ablation for AF for longitudinal thromboembolic morbidity prevention. (Class IIA, Level C limited data)” 
 
“At the time of concomitant cardiac operations in patients with AF, it is REASONABLE to surgically manage the left atrial appendage for longitudinal thromboembolic morbidity prevention. (Class IIA, Level C expert opinion)” 
AHA/ACC/HRS (2014)6
"Surgical excision of the left atrial appendage may be considered in patients undergoing cardiac surgery."
UK NICE (2014)7
"Consider LAA occlusion if anticoagulation is contraindicated or not tolerated and discuss the benefits and risks of LAAO with patient."
EJCTS (2013)8
"We conclude that there has been no proven benefit of surgical LAA exclusion in terms of stroke reduction or mortality benefit… If exclusion is contemplated, devices designed for appendage exclusion should be used rather than a cut-and-sew or stapling technique."
EHRA/EAPCI9,10
"OAC (with VKA or NOACs) is the standard therapy; however, for patients who are contraindicated or refuse (N) OACs… the main indication for LAA occlusion is a relative or absolute contraindication to (N)OACs in patients with AF and a CHADS2 score of ≥1 or CHA2 -DS2 -VASc score ≥ 2."

 

1. Vinay Badhwar, J. Scott Rankin, Ralph J. Damiano, A. Marc Gillinov, Faisal G. Bakaeen, James R. Edgerton, Jonathan M. Philpott, Patrick M. McCarthy, Steven F. Bolling, Harold G. Roberts, Vinod H. Thourani, Rakesh M. Suri, Richard J. Shemin, Scott Firestone, Niv Ad. The Society of Thoracic Surgeons 2017 Clinical Practice Guidelines for the Surgical Treatment of Atrial Fibrillation. The Annals of Thoracic Surgery, 2017; 103: 329-41.
2. Calkins H, Hindricks G, Cappato R, Kim Y-H, Saad EB, Aguinaga L, Akar JG, Badhwar V, Brugada J, Camm J, Chen P-S, Chen S-A, Chung MK, Nielsen JC, Curtis AB, Davies DW, Day JD, d’Avila A, (Natasja) de Groot NMS, Di Biase L, Duytschaever M, Edgerton JR, Ellenbogen KA, Ellinor PT, Ernst S, Fenelon G, Gerstenfeld EP, Haines DE, Haissaguerre M, Helm RH, Hylek E, Jackman WM, Jalife J, Kalman JM, Kautzner J, Kottkamp H, Kuck KH, Kumagai K, Lee R, Lewalter T, Lindsay BD, Macle L, Mansour M, Marchlinski FE, Michaud GF, Nakagawa H, Natale A, Nattel S, Okumura K, Packer D, Pokushalov E, Reynolds MR, Sanders P, Scanavacca M, Schilling R, Tondo C, Tsao H-M, Verma A, Wilber DJ, Yamane T, 2017 HRS/EHRA/ECAS/APHRS/SOLAECE Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation, Heart Rhythm (2017), doi: 10.1016/j.hrthm. 2017.05.012.
3. Ad et al.; Surgical ablation for atrial fibrillation in cardiac surgery. Innovations, vol 5, no 2, March/April 2010.
4. National Institute for Health and Care Excellence. Atrial fibrillation: management, clinical guideline. June 18, 2014.
5. Camm et al.; Guidelines for the management of atrial fibrillation. European Heart Journal, 2010.
6. January et al.; AHA/ACC/HRS Atrial Fibrillation Guideline. JACC Vol. 64, no. 21. December 2, 2014.
7. National Institute for Health and Care Excellence. Atrial fibrillation: management, clinical guideline. June 18, 2014.
8. Dunning et al.; Guideline for the surgical treatment of atrial fibrillation. European Journal of Cardio-Thoracic Surgery. Vol 44. 2013.
9. Meier et al.; EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion. EuroIntervention. 2014 
10. Thambo et al.; The future of left atrial appendage occlusions: When extraordinary claims require evidence… Archives of Cardiovascular Disease 2015 vol 108.